2024 annual financial data
NeuroSense Therapeutics 2024 Operating margin
Direct answer
Operating margin was Not calculable.
Operating income was -9,902,000 USD and net income was -10,210,000 USD.
Operating cash flow was -10,135,000 USD.
Get free NeuroSense Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -9,902,000 USD
- Net income
- -10,210,000 USD
- Operating cash flow
- -10,135,000 USD